Adaptive and innovative Radiation Treatment FOR improving Cancer treatment outcomE (ARTFORCE); a randomized controlled phase II trial for individualized treatment of head and neck cancer.

BMC cancer

Volumn 13, Issue , 2013, Pages

  Heukelom, Jolien ^a   Hamming, Olga ^b   Bartelink, Harry ^b   Hoebers, Frank ^b   Giralt, Jordi ^b   Herlestam, Teresa ^b   Verheij, Marcel ^b   van den Brekel, Michiel ^b   Vogel, Wouter ^b   Slevin, Nick ^b   Deutsch, Eric ^b   Sonke, Jan Jakob ^b   Lambin, Philippe ^b   Rasch, Coen ^b  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; CISPLATIN; MONOCLONAL ANTIBODY; TUMOR MARKER;

ADULT; AGED; ARTICLE; CHEMORADIOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HEAD AND NECK TUMOR; HUMAN; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL; PREDICTIVE VALUE; QUALITY OF LIFE; RADIATION DOSE FRACTIONATION; RADIATION RESPONSE; RANDOMIZED CONTROLLED TRIAL; SQUAMOUS CELL CARCINOMA;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; CISPLATIN; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; QUALITY OF LIFE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

MLCS; MLOWN;

EID: 84874096244     PISSN: None     EISSN: 14712407     Source Type: None    
DOI: 10.1186/1471-2407-13-84     Document Type: Article

References (0)